Is Camurus (OM:CAMX) Still Undervalued On Its FDA CAM2029 Milestone?

Camurus (OM:CAMX) is back in focus after the US Food and Drug Administration accepted the resubmitted New Drug Application for CAM2029 for acromegaly, with a new target review date now set.

See our latest analysis for Camurus.

Against this backdrop, Camurus shares have shown improving momentum, with a 13.16% 1 month share price return and 17.86% 3 month share price return, even though the 1 year total shareholder return is down 12.12% and the 5 year total shareholder return is up 244.48%.

If this kind of regulatory catalyst interests you, it can be useful to broaden your watchlist with other healthcare names using the Simply Wall St screener for 127 healthcare AI stocks.

The recent rebound in Camurus after the CAM2029 update puts the focus squarely on price. After this move and the current discount to analyst targets, does the risk reward still lean toward buyers, or does it now look more balanced?

Most Popular Narrative: 19% Undervalued

Camurus closed at SEK623.5, while the most followed narrative points to a fair value of SEK770.13, which frames the recent rebound in a different light.

The analysts have a consensus price target of SEK770.12 for Camurus based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK930.0, and the most bearish reporting a price target of just SEK610.0.

Read the complete narrative.

Want to understand why this narrative still sees upside at this valuation level? The story hinges on faster top line expansion, shifting margins and a future earnings multiple that is lower than today. Curious which of those inputs really does the heavy lifting in that SEK770 fair value.

Result: Fair Value of SEK770.13 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the Camurus story also faces pressure from product concentration in Buvidal and Brixadi, as well as from reimbursement or funding setbacks in key European markets.

Find out about the key risks to this Camurus narrative.

Next Steps

If this Camurus story has you leaning one way, now is the moment to move fast and test the numbers yourself. To understand why some investors still see upside potential, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond Camurus?

Do not stop with Camurus. Use the Simply Wall St screener to spot other stocks that fit your style before the next round of opportunities passes you by.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com